🤑 It doesn’t get more affordable. Grab this 60% OFF Black Friday offer before it disappears…CLAIM SALE

Wednesday newspaper round-up: AI laws, Microsoft, AstraZeneca

Published 25/10/2023, 08:21
Wednesday newspaper round-up: AI laws, Microsoft, AstraZeneca
UK100
-
MSFT
-
AZN
-

Sharecast - The EU is within “touching distance” of passing the world’s first laws on artificial intelligence, giving Brussels the power to shut down services that cause harm to society, says the AI tsar who has spent the last four years developing the legislation. A forthcoming EU AI Act could introduce rules for everything from homemade chemical weapons made through AI to copyright theft of music, art and literature, with negotiations between MEPs, EU member states and the European Commission over final text coming to a head on Wednesday. – Guardian

The world is at a “tipping point” on debt that threatens to spark a global reckoning after years of government borrowing binges, the boss of HSBC (LON:HSBA) has warned. Noel Quinn, chief executive of the bank, which is one of the world’s biggest, said countries risked being “hit hard” after allowing borrowing to balloon in the wake of the financial crisis and pandemic. – Telegraph

Sales at Microsoft (NASDAQ:MSFT) have surged as the technology giant cashes in on the artificial intelligence (AI) gold rush in a race against Silicon Valley rival Google (NASDAQ:GOOGL). Revenues at Microsoft jumped 13pc to $56.5bn (£46.5bn) as boss Satya Nadella claimed the company was “making the age of AI real”. The technology company has invested in ChatGPT-developer OpenAI and launched a series of AI-powered tools for its Office and Word products in recent months. – Telegraph

Sir Pascal Soriot has said it would be a failure of his leadership if AstraZeneca (NASDAQ:AZN) did not appoint an internal candidate to eventually succeed him, as he committed himself to leading the FTSE 100 drugs company for another five years. Soriot, 64, has overseen the transformation of AstraZeneca since he became chief executive in 2012, turning down a £69 billion takeover offer from Pfizer (NYSE:PFE) and transforming the Cambridge business into one of Britain’s biggest public companies, valued at about £172 billion, after reviving its drugs pipeline. – The Times

Read more on Sharecast.com

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.